TATVA Q4 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹134.1 Cr
verified against source
Revenue YoY
24%
reported change
EBITDA
₹21.8 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Tatva Chintan delivered a strong Q4 FY26 with operating revenue of Rs 134.1 crore, up 24% YoY, driven by exceptional performance in Electrolyte Salts (up 1,378% YoY to Rs 13.1 crore) and Structure Directing Agents (up 52% YoY to Rs 52.5 crore). EBITDA surged 214% YoY to Rs 21.8 crore on improved product mix and operating leverage. The company crossed Rs 500 crore annual revenue milestone in FY26. Management guided for 25% revenue growth and 20-22% EBITDA margin for FY27. Key growth drivers include new pharma product commercialization (Rs 70-75 crore revenue potential), SDA growth of 20% guided for FY27 supported by Euro 7 tailwinds, and hybrid battery electrolyte application starting in Q3 FY27. The Dahej greenfield project remains on track for early 2028 with Phase 1 revenue potential of Rs 400-500 crore. Geopolitical tensions causing 30-40% amine price inflation represent a key risk, though largely passed through to customers. Semiconductor chemicals trial dispatch expected this quarter, with full commercialization targeted for late 2028-early 2029.
Colored figures show movement against the previous available record.
Guidance to track
- Management maintained guidance of approximately 25% revenue growth for FY27 despite geopolitical headwinds, citing robust order visibility and multiple new product introductions. This guidance is supported by existing product momentum and new commercializations.
- EBITDA margin expected in the 20-22% range for FY27, up from 16.25% in Q4 FY26, driven by improved operational efficiency, higher plant utilization, and operating leverage as new products scale up.
- Groundbreaking expected within 60 days (mid-July 2025 target) with 18-20 month construction timeline targeting January-March 2028 for first commercial production. Phase 1 revenue potential of Rs 400-500 crore.
- First plant-scale batch dispatch in current quarter. Product undergoing multiple validation cycles at integrator and customer levels before final commercialization expected by end of 2028.
Risks flagged
- Amines prices increased 30-40% due to geopolitical tensions following the Iran situation in March. While most customers accepted price pass-through, some only allow raw material price impact pass-through, creating margin pressure in certain contracts.
- Analyst raised concerns about ACT (likely Atorvastatin) volumes impacting customer demand. Management clarified Tatva has insignificant volume share in customers' total demand, providing resilience, though this represents a segment-level risk for pharmaceutical intermediates.
- SDA market has only two suppliers who maintain balance - management confirmed maximum market share per customer capped at ~70% as customers deliberately keep both suppliers engaged. This structural dynamic limits upside from individual customer relationships.
- Project was delayed 4-6 weeks due to detailed engineering feedback requiring process optimization trials. While this reduced reactor count and improved long-term efficiency, similar feedback loops during construction phase could impact the 18-20 month timeline.
Key quotes
- We have already maintained that we will be growing the revenue by around 25%. And EBITDA should be in range of somewhere around 20 to 22%. On a very realistic basis so we'll stick to that.
- The increased prices have gradually been implemented on new orders. With multiple developments getting into commercial phase, we foresee the momentum of growth to continue for next two years. Once the new greenfield project at Dahej goes online, it will bring in the next phase of growth from financial year 28-29.
- We are also witnessing improved customer engagement across key geographies with business discussions becoming more structured. Given the specialized nature of this chemistry and our established position in the segment, we continue to remain positive on the long-term prospects of the SDA business.
Research modules